ClinicalTrials.gg
RecruitingNCT06890897Updated Apr 27, 2025

Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia

An interventional study of Esketamine group and PRF group in Zoster; Herpes, Trigeminal Neuralgia (Etiology), sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Herpes Zoster by Beijing Tiantan Hospital — 11 open to participants now, 12 under way, none of them phase 3. Herpes Zoster · Beijing Tiantan Hospital.

Planned enrollment
11th of 12
174 · median 750
Started
2025
with 10 others
No phase
12 of 12
11 open now
Primary completion
2026-06
later than 1 of 11 live
Registered
2nd of 12
by date

Among the 12 studies in Herpes Zoster by Beijing Tiantan Hospital, this one is the 11th largest by planned enrollment, is one of 11 that started in 2025, is one of 12 with no phase, reaches primary completion later than 1 of the 11 other live ones, and was the 2nd registered.

Herpes Zoster

300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

11 of the 12 studies in Herpes Zoster by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Herpes Zoster by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

To assess the 1-month effects and safety of esketamine combined PRF and standardized treatment to relieve pain in patients with acute/subacute zoster-related trigeminal neuralgia(ZRTN).

Read the detailed description

The investigators aim to investigate whether or not esketamine combined PRF and standardized treatment to relieve pain in patients with acute/subacute ZRTN , and seek a safe, and effective treatment for refractory patients with ZRTN

03

Conditions studied

  • Zoster; Herpes, Trigeminal Neuralgia (Etiology)

Keywords

  • acute/subacute zoster-associated trigeminal neuralgia
  • esketamine
  • pulsed radiofrequency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years;
  2. History of HZ within the last three months;
  3. Lesions located in the trigeminal nerve or its branches innervated regions;
  4. Numeric Rating Scale (NRS) pain score≥4 (NRS, 0 = no pain, 10= worst possible pain) with pharmacotherapy;
  5. Planned to perform CT-guided PRF treatment of the Gasserian ganglion .

Exclusion criteria

Exclusion Criteria:

  1. Obstructive sleep apnoea syndrome;
  2. Those who receive other invasive treatments, such as spinal cord stimulation;
  3. A history of systemic immune diseases, organ transplantation, or cancers;
  4. A history of severe cardiopulmonary, hepatic or renal dysfunction;
  5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
  6. Comorbid hyperthyroidism or phaeochromocytoma;
  7. Recent history of drug abuse;
  8. Having to esketamine;
  9. Communication difficulties.

Withdrawal criteria

  1. Lost to follow-up during the study;
  2. Not perform the planned operation;
  3. Receiving other treatment regimes during the study period;
  4. Not suitable for continuing the study for emerging severe comorbidities or special physiological changes during the study;
  5. Voluntary withdrawal from the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    Esketamine group

    Besides PRF plus standardized treatment, patients will also receive intravenous infusion of Esketamine ;

    Drug: Esketamine group

  • Active comparator
    control group

    Patients will only receive PRF plus standardized treatment

    Drug: PRF group

Interventions

  • DrugEsketamineStudies of EsketamineEsketamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients in the esketamine group will receive intravenous infusion of esketamine besides PRF+standardized treatment.The formula will be intravenous infusion of 0.5mg/kg of esketamine diluted in 50 mL normal saline, starting with intravenous injection of 10 mg of esketamine for 1 minute, and maintaining a dose 8 mg/h.The infusion rate will be adjusted the parameter according to the tolerance of the patients

    Also known as: Esketamine + PRF+standardized treatment

  • DrugP-prfStudies of P-prfP-prf pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients in the control group will receive PRF+standardized treatment

    Also known as: PRF + standardized group

06

What researchers measure

Primary outcomes

  1. the NRS score at 1 month after treatment.

    The Numeric Rating Scale (NRS) score is a way to quantify the degree of subjective feelings such as pain using numbers. Generally, 0 represents no pain, and 10 represents the most severe pain.A higher score indicates more severe pain

    Time frame: 1-month period

Secondary outcomes

  1. the 12-item Short-Form Health Survey (SF-12) score

    Quality of life (QoL) assessed by the SF-12 score (range 0-100, with higher scores indicating better health status)

    Time frame: at 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment

  2. the Pittsburgh Sleep Quality Index (PSQI) score

    Sleep quality measured by PSQI score(range 0-21, with higher scores indicating poorer sleep quality)

    Time frame: at 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment

  3. the Patient Global Impression of Change scale (PGIC)

    The proportion of patients with a response of "no change", "minimally improved", "much improved" or "very much improved" on PGIC

    Time frame: at 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment

  4. Analgesics consumption

    the type of analgesics and analgesics consumption

    Time frame: at 1 day, 1 week, 2 weeks, 1 month, 2 months, 3 months after treatment

  5. Safety assessments

    intraoperative complications, PRF-related complications, Eskatamine-related complications

    Time frame: at 0 day, 1 day, 1 week, 2 weeks,1 month, 2 months, 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Not yet

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2026, 14 months after the start.

Of 34 interventional studies with no phase under Herpes Zoster, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 14 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 24, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06890897
Collaborators
Beijing Xiaotangshan Hospital, The First Hospital of Fangshan District,Beijing, Beijing Ditan Hospital, Hengshui People's Hospital
Responsible party
Fang Luo (Director of Department of Day surgery and Pain Management Affiliation, Beijing Tiantan Hospital) — Principal investigator
First posted
Mar 24, 2025
Start date
Apr 1, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Apr 27, 2025

Study contacts

Fang Luo, M.D.
Contact
13611326978@163.com
+86 13611326978
Fang Luo, M.D.
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion